Diabetes drug sotagliflozin tested as potential blood thinner
NCT ID NCT06933056
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study at the University of Michigan will test whether the diabetes drug sotagliflozin can reduce platelet activity as well as FDA-approved antiplatelet drugs like aspirin, clopidogrel, and apixaban. Twenty healthy volunteers will take each drug for two weeks, and researchers will measure blood samples for clotting and platelet function. The goal is to see if sotagliflozin might have hidden benefits for heart health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sotagliflozin
- What this could lead to
- If sotagliflozin shows strong antiplatelet effects, it could point toward a new use for this diabetes drug in preventing blood clots.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world conditions, and the drug may not outperform existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATELET FUNCTION AND REACTIVITY TESTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States